Home
Home
  • Home
  • About Us About Us
    • Overview
    • Who we are
    • Why we provide advice
    • What are health technologies
    • Meetings
    • News
    • Who we work with
    • Contact Us
  • What We Do What We Do
    • Overview
    • Our Strategy
    • Work programme
    • Range of advice products
    • Quarterly Bulletin of advice
    • Early HTA Advice Service
  • Our Advice
  • Request Advice Request Advice
    • Overview
    • Form for requesting advice
  • Get Involved Get Involved
    • Overview
    • Contribute to advice
    • NHS boards
    • Patient and Public Involvement
    • Industry Involvement
    • Observe a council meeting
    • DOI Form

Advice Statement

  • Home
  • Our Advice
  • PET-CT for male genitourinary cancers

Title

Output Type

Speciality

Published

Title

PET-CT for male genitourinary cancers

Output Type

Advice Statement

Speciality

Cancer, Genitourinary system

Published

5 December 2017

Recommendation for NHSScotland

  • There is insufficient evidence on the clinical and cost-effectiveness of FDG PETCT and none of the identified studies reported any long-term oncological or quality of life outcomes resulting from changes in patient management.
  • It is not currently possible to draw any conclusions on the effectiveness for staging and/or restaging of patients with penile or testicular cancers in the NHS in Scotland.
  • Current evidence on FDG PET-CT for penile or testicular cancer patients appears to be at stage 2 or 3 of the IDEAL-D framework. Future studies should therefore be prospective, blind, controlled, diagnostic studies, or economic evaluations.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

What were we asked to look at?

Is FDG PET-CT clinically and costeffective in the staging and/or restaging of disease in patients with penile or testicular cancers?

Why is this important?

Penile cancer is rare in developed countries and there are typically fewer than 100 people diagnosed with this disease every year in Scotland. Testicular cancer is relatively more common, and will lead to approximately 200 people being newly diagnosed in Scotland each year. In both penile and testicular cancers, conventional CT imaging has been recommended at specified points during the staging and/or restaging process. 18F-2-fluoro-2-deoxy-D-glucose (FDG) is a radioisotope given to patients prior to PET-CT hybrid imaging. The resulting images could potentially enhance the information yielded by current imaging techniques and other diagnostic information used to inform staging and/or restaging.

Referred by

The Scottish PET-CT Working Group

 

Download icon
Download Advice
pdf (268 KB)
Download icon
Download Evidence Note
pdf (877 KB)

Connect with Us

Please let us know if you'd like to receive regular updates on our work.


Last Updated: 31 January 2022

Scottish Health Technologies Group

© 2021, All rights reserved

  • Accessibility
  • Respecting your privacy
  • Cookies
  • Healthcare Improvement Scotland Website
  • Find us on Twitter
  • Freedom of Information

Tell us what you think


We'd love to hear your views

Was our advice useful?  Did you find what you were looking for on our website?